BONESUPPORT
Injectable osteoconductive biomaterials for the treatment of fragility fractures.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | SEK378m | Post IPO Equity | |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 54 % | 80 % | 52 % | 42 % | 40 % | 32 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (34 %) | (17 %) | 5 % | 19 % | 23 % | 32 % | 38 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (40 %) | (21 %) | 41 % | 15 % | 17 % | 25 % | 30 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 25 % | 16 % | 10 % | 8 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
BONESUPPORT is a medical technology company specializing in the development and commercialization of innovative injectable bioceramic bone graft substitutes. These substitutes are designed to promote bone healing and regeneration, providing an alternative to traditional bone grafts. The company primarily serves orthopedic surgeons, hospitals, and clinics that treat patients with bone disorders, fractures, and other skeletal conditions.
Operating in the global healthcare market, BONESUPPORT focuses on regions including Europe, North America, and Asia. The company's flagship product, CERAMENT, is a synthetic bone graft substitute that can be combined with drugs to enhance bone healing. This product is particularly useful in treating bone infections, fractures, and defects, offering a less invasive and more effective solution compared to traditional methods.
BONESUPPORT's business model revolves around research and development (R&D), manufacturing, and sales of its bioceramic products. The company invests heavily in clinical trials and scientific research to validate the efficacy and safety of its products. Revenue is generated through the direct sale of these products to healthcare providers and through partnerships with other medical companies.
The company was founded by Professor Lars Lidgren in the early 2000s, with the vision of creating synthetic solutions to improve the quality of life for patients with bone disorders. Over the years, BONESUPPORT has expanded its product pipeline to include combination products that release drugs to further enhance bone healing. The company continues to innovate, aiming to broaden the clinical applications of its technology.
Key personnel include Kristina Ingvar, who oversees global quality and regulatory compliance, ensuring that BONESUPPORT meets stringent international standards. The company collaborates with various partners worldwide to expand its reach and impact in the medical field.
Keywords: bioceramic, bone graft, orthopedic, CERAMENT, bone healing, synthetic, healthcare, medical technology, R&D, global market.